Stock SHJBF SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Shanghai Junshi Biosciences Co., Ltd. OTC Markets

Equities

SHJBF

CNE100003FF7

Market Closed - OTC Markets
Other stock markets
 07:21:46 20/03/2024 pm IST 		5-day change 1st Jan Change
1.86 USD -9.71% Intraday chart for Shanghai Junshi Biosciences Co., Ltd. -.--% -13.49%
13/06 Junshi Biosciences' Cancer Drug Gets Registration Certificate from Chinese Regulator MT
12/06 Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer
GL
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer
AQ
Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint
GL
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
GL
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
AQ
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
GL
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
GL
Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority
GL
Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer
GL
Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine
GL
Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients
AQ
Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients
GL
Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA
AQ
Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA
GL
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI as Treatment for Nasopharyngeal Carcinoma
AQ
Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19
GL
FDA Approves LOQTORZI In All Lines Of Treatment For Recurrent Or Metastatic Nasopharyngeal Carcinoma
AQ
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
AQ
Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023
GL
Junshi Biosciences Announces 2023 Interim Financial Results and Provides Corporate Updates
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1877 Stock
  4. SHJBF Stock
  5. News Shanghai Junshi Biosciences Co., Ltd.
  6. Press Releases